Business

Cocrystal Pharma Inc. (NASDAQ: COCP) Jumps 9% on Promising CDI-45205 Inhibitor Results against COVID-19 Variants

Cocrystal Pharma Inc. (NASDAQ: COCP) jumped 9.6% after announcing that the company’s lead preclinical SARS-CoV-2 3CL proteases inhibitor CDI-45205 was actives against COVID-19 and two other common SARS-CoV-2 strains. 

CDI-45205 demonstrated antiviral activity 

In vitro studies assessing CDI-45205 antiviral activity and its analogs in VeroE6-eGFP cells infected with SARS-CoV-2 (Wuhan strain), the UK variant (B.1.1.7), and the South African strain (B.1.351) were undertaken by a third-party laboratory contracted by Cocrystal. CDI-45205 and its analogs were found to have superior antiviral effectiveness against both SARS-CoV-2 strains, outperforming SARS-CoV-2 (Wuhan strain). 

The trial contained two reference inhibitors: remdesivir, an FDA-approved SARS-CoV-2 RNA-dependent RNA polymerase inhibitor, and PF-00835231, another SARS-CoV-2 3CL protease inhibitor. In a P-glycoprotein efflux inhibitor’s absence, CDI-45205 had excellent antiviral activity against the UK variant, with an EC50 of 1.9 uM (remdesivir EC50 0.6 uM; PF-00835231 EC50 >100 uM) and against the South African strain, with an EC50 of 2.5 uM (remdesivir EC50 0.8 uM; PF-008352.

CDI-45205 effective against SARS-CoV-2 variants 

Sam Lee, the interim Cocrystal CEO, said that the results with CDI-45205 against SARS-CoV-2 and two significant SARS-CoV-2 subtypes are pretty encouraging. The company plans to continue testing for antiviral effectiveness against other new variants, including the Indian variant. Most importantly, the findings contribute to the growing amount of CDI-45205 preclinical research. Lee said that the new findings imply that Cocrystal’s protease inhibitor could be an effective treatment for COVID-19, which SARS-CoV-2 and its variants cause. Additionally, Cocrystal researchers are investigating broad-spectrum oral protease inhibitors and replication inhibitors for the treatment of COVID-19 utilizing the company’s novel structure-based drug discovery tech platform.

In intraperitoneal injection pharmacokinetic studies in mice and rats, CDI-45205 exhibited high bioavailability and no cytotoxicity against several human cell types. Recently the company proved that remdesivir has a substantial synergistic impact.

Leave a Comment

Your email address will not be published.

*